Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$89.22

0.75 (0.85%)

, CHRS

Coherus Biosciences

06:20
09/15/17
09/15
06:20
09/15/17
06:20

AbbVie price target raised to $100 from $85 at Piper Jaffray

Piper Jaffray analyst Richard Purkiss raised his price target for AbbVie (ABBV) to $100 after pushing out a U.S. biosimilar entry for Humira by two years. The recent denials by the Patent Trial and Appeal Board of all four of Coherus Bioscience's (CHRS) inter partes review petitions reinforce the patentability of Humira's formulation, Purkiss tells investors in a research note. The analyst pushed out his view of the likely timing of the first U.S. biosimilar launch versus Humira to the second half of 2022 from the second half of 2020. He estimates Humira will still account for 58% of AbbVie's total revenue in 2020. The analyst reiterates an Overweight rating on the shares.

ABBV

AbbVie

$89.22

0.75 (0.85%)

CHRS

Coherus Biosciences

  • 25

    Sep

  • 27

    Sep

ABBV AbbVie
$89.22

0.75 (0.85%)

09/13/17
RHCO
09/13/17
NO CHANGE
RHCO
AbbVie data increases confidence in RA opportunity, says SunTrust
SunTrust analyst John Boris says that data on AbbVie's (ABBV) UPAD for rheumatoid arthritis shows that its efficacy "appears competitive" with that of Pfizer's (PFE) Xeljanz/XR. The analyst says that the data increases his confidence in AbbVie's opportunity in RA. He keeps a $95 price target and a Buy rating on the shares.
09/11/17
COWN
09/11/17
NO CHANGE
Target $95
COWN
Market Perform
AbbVie price target raised to $95 from $70 at Cowen
Cowen analyst Steve Scala raised his price target on Abbvie to $95 from $70 to reflect his raised estimates to account for higher Humira forecasts. The company received an important victory regarding an IPR targeting a Humira formulation, which he feels will allow Abbvie to hold Humira sales at least flat during 2020-2022. This has big bottom line implications, said Scala, who maintained his Market Perform rating on Abbvie shares.
09/08/17
MAXM
09/08/17
NO CHANGE
MAXM
Coherus Biosciences price target lowered to $20 from $40 at Maxim
Maxim analyst Jason McCarthy cut his price target on Coherus (CHRS) after several petitions for Inter Partes review of AbbVie's (ABBV) Humira were denied. As a result of this development, the analyst thinks that Coherus may not be able to launch its CHS-1420 "for years" after its approval which he believes could come in 2019.
09/08/17
CANT
09/08/17
NO CHANGE
Target $45
CANT
Overweight
Things keep getting better for Dermira, says Cantor
In a research note titled "Things Just Keep Getting Better Ahead of Stock Moving Catalysts In 2018," Cantor Fitzgerald analyst Louise Chen says she sees three things that may be driving Dermira (DERM) shares higher. New data which support and improve the commercial opportunity for Cimzia and DRM04, positive Phase 2b data from AbbVie's (ABBV) atopic dermatitis drug, which could help expand the market and the opportunity for Dermira's Lebrikizumab, and positive meetings with investors at a healthcare conference yesterday, Chen tells investors. The analyst keeps an Overweight rating on the shares with a $45 price target.
CHRS Coherus Biosciences

07/10/17
KEYB
07/10/17
DOWNGRADE
KEYB
Sector Weight
Medpace downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Donald Hooker downgraded Medpace Holdings (MEDP) to Sector Weight ahead of the Q2 earnings report citing valuation. The analyst also believes issues at "important" client Coherus Biosciences (CHRS) could adversely impact the relationship in the near term. Hooker views 2017 as a "rocky year" and recommends "temporarily" stepping to the sidelines with respect to Medpace shares.
06/13/17
FBCO
06/13/17
NO CHANGE
Target $24
FBCO
Outperform
Coherus price target lowered to $24 from $38 at Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target on Coherus Biosciences to $24 from $38, stating that there is greater risk around the development path for its Neulasta biosimilar after the FDA's complete response letter. Young reiterates that she is "cautiously optimistic" the company can address issues over the next six months, though that makes this time period critical for CHS-1701. For now, she has decreased her probability of success for CHRS-1701 to 65% from 90% in U.S. and Europe, though she keeps an Outperform rating on Coherus shares.
06/12/17
LEER
06/12/17
NO CHANGE
Target $161
LEER
Market Perform
Amgen price target raised to $161 on Neulasta biosimilar delay at Leerink
Leerink analyst Geoffrey Porges noted that Coherus Biosciences (CHRS) received a complete response letter from the FDA for its biosimilar to Amgen's (AMGN) Neulasta, which he views as likely delaying its launch by at least a year. However, the "windfall" is offset by the Supreme Court decision that "effectively eliminates" the 6-month delay for biosimilars associated with notification, Porges tells investors. Based on his forecast for a six-month delay in the timing of a Neulasta biosimilar launch in the U.S., to the second quarter of 2018 from the fourth quarter of 2017, Porges increased his 2018 Amgen revenue forecast by $500M and raised his price target to $161 from $159, though he keeps a Market Perform rating on the stock.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

13:17
09/19/17
09/19
13:17
09/19/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
09/19/17
09/19
13:16
09/19/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Holdings

$76.15

-1.53 (-1.97%)

13:15
09/19/17
09/19
13:15
09/19/17
13:15
Options
HCA Holdings put volume heavy and directionally bearish »

Bearish flow noted in HCA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
09/19/17
09/19
13:15
09/19/17
13:15
General news
Fed Policy Outlook: FOMC began its 2-day meeting »

Fed Policy Outlook: FOMC…

ICPT

Intercept

$95.75

0.87 (0.92%)

13:11
09/19/17
09/19
13:11
09/19/17
13:11
Conference/Events
Intercept management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

WHR

Whirlpool

$170.86

0.02 (0.01%)

13:10
09/19/17
09/19
13:10
09/19/17
13:10
Hot Stocks
Whirlpool ticks lower after August appliance data »

Shares of Whirlpool moved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIF

Tiffany

$90.95

1.98 (2.23%)

13:05
09/19/17
09/19
13:05
09/19/17
13:05
Options
Tiffany call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

13:00
09/19/17
09/19
13:00
09/19/17
13:00
General news
FOMC forecast revisions »

FOMC forecast revisions…

PTLA

Portola Pharmaceuticals

$56.57

1.62 (2.95%)

12:58
09/19/17
09/19
12:58
09/19/17
12:58
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola selloff today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

KR

Kroger

$21.29

-0.1501 (-0.70%)

12:55
09/19/17
09/19
12:55
09/19/17
12:55
Options
Kroger put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

  • 30

    Nov

PTLA

Portola Pharmaceuticals

$56.57

1.62 (2.95%)

12:51
09/19/17
09/19
12:51
09/19/17
12:51
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

FCAU

Fiat Chrysler

$17.10

0.275 (1.64%)

12:49
09/19/17
09/19
12:49
09/19/17
12:49
Hot Stocks
FCA US recalling 443,712 U.S.-market heavy-duty pickups, medium-duty trucks »

FCA US LLC is voluntarily…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$75.16

-0.15 (-0.20%)

12:48
09/19/17
09/19
12:48
09/19/17
12:48
Hot Stocks
Microsoft Azure IP Advantage available in China on October 1 »

Microsoft said on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Oct

AA

Alcoa

$45.77

0.86 (1.91%)

12:45
09/19/17
09/19
12:45
09/19/17
12:45
Options
Alcoa call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$4.15

-0.25 (-5.68%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37
Conference/Events
Noodles & Company management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ENDP

Endo

$8.34

-0.26 (-3.02%)

, JNJ

Johnson & Johnson

$135.14

-0.24 (-0.18%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37
Hot Stocks
Schneiderman, coalition of AGs expand multistate probe into opioid crisis »

New York Attorney General…

ENDP

Endo

$8.34

-0.26 (-3.02%)

JNJ

Johnson & Johnson

$135.14

-0.24 (-0.18%)

TEVA

Teva

$17.14

0.15 (0.88%)

AGN

Allergan

$218.48

-3.06 (-1.38%)

ABC

AmerisourceBergen

$80.24

-0.43 (-0.53%)

CAH

Cardinal Health

$66.37

-0.7 (-1.04%)

MCK

McKesson

$150.02

1.6 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 27

    Sep

  • 17

    Oct

LXRX

Lexicon

$12.81

0.44 (3.56%)

, IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37
Hot Stocks
Lexicon announces European Commission approves Xermelo »

Lexicon Pharmaceuticals…

LXRX

Lexicon

$12.81

0.44 (3.56%)

IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

12:35
09/19/17
09/19
12:35
09/19/17
12:35
General news
Today's U.S. reports »

Today's U.S. reports…

LEG

Leggett & Platt

$45.25

-0.635 (-1.38%)

12:34
09/19/17
09/19
12:34
09/19/17
12:34
Conference/Events
Leggett & Platt management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

, VIA

Viacom

$37.45

-0.4 (-1.06%)

12:32
09/19/17
09/19
12:32
09/19/17
12:32
Periodicals
Viacom leak may have compromised digital properties, Gizmodo reports »

A security researcher…

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

VIA

Viacom

$37.45

-0.4 (-1.06%)

VIAB

Viacom

$27.32

-0.35 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ACTG

Acacia Research

12:32
09/19/17
09/19
12:32
09/19/17
12:32
Hot Stocks
Acacia Research shares trade higher amid insider buying »

A number of insiders at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDOT

Green Dot

$48.82

0.79 (1.64%)

12:30
09/19/17
09/19
12:30
09/19/17
12:30
Conference/Events
Green Dot management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ADBE

Adobe

$155.77

1.28 (0.83%)

12:30
09/19/17
09/19
12:30
09/19/17
12:30
Options
Adobe attracts a pre-earnings call writer »

Adobe attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 22

    Oct

ENDP

Endo

$8.34

-0.26 (-3.02%)

, JNJ

Johnson & Johnson

$134.95

-0.43 (-0.32%)

12:28
09/19/17
09/19
12:28
09/19/17
12:28
Hot Stocks
Michigan AG says 41 state attorneys general now involved in opioid probe »

Michigan Attorney General…

ENDP

Endo

$8.34

-0.26 (-3.02%)

JNJ

Johnson & Johnson

$134.95

-0.43 (-0.32%)

TEVA

Teva

$17.14

0.15 (0.88%)

AGN

Allergan

$218.49

-3.05 (-1.38%)

ABC

AmerisourceBergen

$80.20

-0.47 (-0.58%)

CAH

Cardinal Health

$66.36

-0.71 (-1.06%)

MCK

McKesson

$149.89

1.47 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 27

    Sep

  • 17

    Oct

EFX

Equifax

$94.55

0.17 (0.18%)

12:27
09/19/17
09/19
12:27
09/19/17
12:27
Periodicals
Massachusetts Attorney General files lawsuit against Equifax, Reuters reports »

The State of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.